

Our testing process



STEP 1

Your healthcare professional orders DecisionDx-SCC



STEP 2

Castle Biosciences works with your healthcare professional's laboratory to obtain a tissue sample from your original biopsy



STEP 3

Our laboratory analyzes your tissue sample with our genomic test



STEP 4

Test results are sent to your healthcare professional so that your individual results can be discussed and used to determine the next steps in your care

How is the test paid for?

Castle Biosciences is committed to providing high quality molecular testing to all patients. We do not want financial concerns to be a barrier to patients accessing critical healthcare information. We will work with all insurance providers, including Medicare, Medicaid, commercial insurers, and Veterans Affairs (VA), to secure payment coverage for our testing.

For those who may need additional assistance with their Castle test, we offer a comprehensive patient assistance program to all patients. If you have any questions, please contact us by calling 866-788-9007, option 3 or emailing reimbursement@castlebiosciences.com.

For more information visit:
mySCCskincancer.com

1. SEER data release. 2019.
2. American Cancer Society. Cancer.org. 2024.
3. Skin Cancer Foundation. skincancer.org. 2024.
4. Arron et al. *JDD*. 2021.
5. Singh et al. *CCID*. 2022.
6. Ibrahim et al. *Future Oncology*. 2021.



©2024 Castle Biosciences Inc.
DecisionDx®-SCC is a
trademark of Castle Biosciences, Inc.
DDXSCC-003v2-012024

DecisionDx
►SCC



Patient Resource Guide

Understanding your individualized risk after a cutaneous squamous cell carcinoma (SCC) diagnosis



What is cutaneous squamous cell carcinoma?

Cutaneous SCC occurs when squamous cells of the skin are damaged and begin to grow abnormally.

Damage to these skin cells is typically triggered through exposure to ultraviolet (UV) radiation from sources such as the sun.

While SCC is treatable if caught early, it can be very aggressive if it spreads.

2 million+

Estimated new diagnoses in the US per year¹

20%

of all skin cancers are SCC. It is the second most common form of skin cancer after basal cell carcinoma^{2,3}

~16K

people die each year from SCC¹

What is DecisionDx®-SCC?

DecisionDx-SCC is a gene expression profile test that looks at the activity of 40 different genes within your tumor to better understand your individualized risk of the cancer spreading to other parts of your body.

DecisionDx-SCC provides you with personalized test results that can help you and your physician make decisions^{4,5} about:



Treatment, including radiation



Imaging



Follow-up appointments with your dermatologist



Additional visits with other specialties (referrals)

Why DecisionDx-SCC?

Traditional approaches to determine the risk level of a SCC tumor may miss patients with aggressive tumor biology. While there are many different factors that go into assessing risk (such as size, depth, and other factors that may not be able to be seen without a microscope), tumor biology is not taken into consideration.



What do the results mean?

DecisionDx-SCC test looks at your specific tumor's biology and will provide you with one of the class results below.⁶



These results provide you with personalized information that can improve your ability to:

- Understand your personalized disease risk
- Acknowledge what treatment interventions are appropriate
- Create a plan of action to best fight back against your SCC cancer